Pancreatic cancer vaccine shows promise

mRNA Vaccine Shows Promise In Pancreatic Cancer Trial
Results from a trial of an mRNA vaccine for pancreatic cancer have shown that the vaccine reduces the chance of the cancer recurring in patients who initially respond.
Pancreatic cancer RNA vaccine shows durable T cell immunity
Memorial Sloan Kettering Cancer Center researchers have found RNA neoantigen vaccines that generate long-lived, functional CD8+ T cells in patients with pancreatic ductal adenocarcinoma (PDAC), potentially delaying disease recurrence.
Vaccine targeting pancreatic cancer shows promise in new study of clinical trial
A clinical trial from Memorial Sloan Kettering Cancer Center looked at the effects of a targeted mRNA vaccine on early-stage pancreatic cancer patients.
Can mRNA vaccines help in the fight against pancreatic cancer?
There is new hope in the fight against pancreatic cancer after early trials showed that personalized mRNA vaccines can target and reduce malignant tumors. NBC News medical contributor Dr. Kavita Patel reports on the vaccine’s success against pancreatic cancer,
Vaccine shows promise for treating pancreatic cancer, study shows
A personalized mRNA vaccine appeared to reduce the chances of pancreatic cancer returning after surgery, according to a study published in the journal Nature.
A Vaccine For Pancreatic Cancer Continues To Show Promise
In a small trial, nearly half of pancreatic cancer patients who received an mRNA vaccine for the disease had no relapse three years later.
Experimental vaccine for common cancer shows potential in clinical trial
A Memorial Sloan Kettering phase 1 clinical trial revealed an immune response in some pancreatic cancer patients. Study co-author Dr. Vinod Balachandran talks about the impact on future cancer care.
Pancreatic cancer vaccine showing promise in early trial
Pancreatic cancer is the 10th deadliest form of cancer in the United States, according to the National Cancer Institute.
Vaccine shows promise for pancreatic cancer, study finds
Adding a personalized mRNA vaccine to standard treatment could offer new hope for pancreatic cancer patients, a small yet promising study from Memorial Sloan Kettering Cancer Center.
Trial shows promise of mRNA vaccines in treating pancreatic cancer
The phase 1 trial results, published Feb. 19 in Nature, evaluated the personalized mRNA neoantigen vaccine autogene cevumeran in combination with surgery, immunotherapy drug atezolizumab and chemotherapy in patients with pancreatic ductal adenocarcinoma.
Can You Personalize Your Pancreatic Cancer Vaccinations?
As per a new study, the potential of mRNA vaccines offers a personalized treatment for patients with pancreatic cancer.
Experimental vaccine for common cancer shows potential in clinical trial; here’s what we know
A promising new mRNA-based vaccine for pancreatic cancer has shown potential in reducing the recurrence of the disease ...
Analyst Confident In Moderna's Cancer Vaccine But Highlights Other Challenges
EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...
The Daily Pennsylvanian5d
Here’s how Penn researchers are using mRNA technology to treat cancer, celiac disease
Penn researchers are developing new treatments using mRNA technology to combat a range of diseases, namely celiac disease ...